The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Retension Pharmaceuticals joined TRex Bio in pricing an offering on Thursday, while AI drug discovery specialist Iambic Therapeutics and RNAi biotech City Therapeutics set terms for their coming share sales.

    Updated 9 hours ago
  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris
    Image attribution tooltip

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx falls as Sjögren’s setback offsets celiac drug progress

    A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart. 

  • A neurodegenerative disease concept illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    A Takeda spinout builds case for its Parkinson’s drug

    Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

  • Banners marking the 2025 American Society of Clinical Oncology's annual meeting hang from the ceiling of a conference hall.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip

    The top biopharma conferences in 2027

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

  • An illustration of CRISPR-cas9 gene editing
    Image attribution tooltip
    del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
    Image attribution tooltip
    Gene editing

    Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

    Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.

  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Trump administration

    5 FDA decisions to watch in the fourth quarter of 2026

    The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

    A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.

  • A set of three EU flags blows in the wind in front of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds

    The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.

  • Photomicrograph of a diffuse large B-cell lymphoma (DLBCL) a type of non-Hodgkin lymphoma.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

    The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

  • An illustration of a cancerous tumor inside the lungs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ArriVent collapses on disappointing lung cancer data

    More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share. 

  • Illustrated streptococcus pneumoniae bacteria are colored yellow against a dark background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

    The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

    The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.

  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Shionogi pays $2B to acquire a rare disease startup

    The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.

  • A scientist in white jacket operates radiopharmaceutical manufacturing equipment.
    Image attribution tooltip
    Courtesy of GE HealthCare
    Image attribution tooltip

    GE HealthCare to acquire Sofie Biosciences for $945M

    The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.

  • A sign spelling Novartis hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

    In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking

    The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

  • Digital tablet displaying “AI AGENTS” with connected icons representing data, cloud computing and automated tools.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    An AI agent made a tiny drug R&D mistake. Then it kept going.

    The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Viatris’ purchase of Pacira Biosciences is the first acquisition of a publicly traded biopharmaceutical company in more than two months, according to BioPharma Dive data.

    Updated Oct. 8, 2026
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    3 takeaways from a European obesity scientific meeting

    Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.

  • A close-up of a child's hands with red, irritated skin on the wrist.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pfizer’s eczema drug clears skin in mid-stage trial

    Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly, Foghorn part ways; Wave’s FDA-approved plans

    The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Hengrui’s $2.6 billion deal with Novo is its sixth with a major U.S. or European drugmaker since the start of 2025, the most of any China-based biopharmaceutical company over that timeframe.

    Updated Sept. 29, 2026
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi, Regeneron broaden alliance to find their next Dupixent

    The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.

  • A picture of the exterior of the US Department of Health and Human Services. In front of the building is a black sign designating the building's name.
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    HHS kicks off new programs to speed clinical trials as Chinese competition looms

    The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.